| Julie Hoover-fong, MD | |
|
600 N Wolfe St, Baltimore, MD 21287-0005 | |
| (410) 955-3071 | |
| Not Available |
| Full Name | Julie Hoover-fong |
|---|---|
| Gender | Male |
| Speciality | Medical Genetics And Genomics |
| Experience | 29 Years |
| Location | 600 N Wolfe St, Baltimore, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134171119 | NPI | - | NPPES |
| 434430800 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | D57914 (Maryland) | Secondary |
| 207SG0201X | Medical Genetics - Clinical Genetics (m.d.) | D57914 (Maryland) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Johns Hopkins Hospital, The | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Johns Hopkins University | 8921903147 | 2692 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
The Canadian Diabetes Association applauds the Government of Saskatchewan for increasing access to insulin detemir for residents of Saskatchewan living with diabetes. Insulin detemir, also known as Levemir, has been added to the Saskatchewan Drug Formulary, under Exception Drug Status (EDS) effective July 1, 2009. As well, the updated formulary now includes NovoRapid-NOO, Apidra-AVT and Humalog-LIL within its Revised Exception Drug Status Criteria.
Unfortunately, there are too many examples that show how our system can fail to meet patients' needs. These problems are not a reflection on the many doctors, nurses and other professionals who work tirelessly to deliver the highest quality care they can.
Compugen Ltd., a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer immunotherapy treatments for solid tumors, including the potential for drug combination with current immune checkpoint blockers.
› Verified 4 days ago
| Entity Name | Johns Hopkins University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922008549 PECOS PAC ID: 8921903147 Enrollment ID: O20031215000719 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
The Canadian Diabetes Association applauds the Government of Saskatchewan for increasing access to insulin detemir for residents of Saskatchewan living with diabetes. Insulin detemir, also known as Levemir, has been added to the Saskatchewan Drug Formulary, under Exception Drug Status (EDS) effective July 1, 2009. As well, the updated formulary now includes NovoRapid-NOO, Apidra-AVT and Humalog-LIL within its Revised Exception Drug Status Criteria.
Unfortunately, there are too many examples that show how our system can fail to meet patients' needs. These problems are not a reflection on the many doctors, nurses and other professionals who work tirelessly to deliver the highest quality care they can.
Compugen Ltd., a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer immunotherapy treatments for solid tumors, including the potential for drug combination with current immune checkpoint blockers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Julie Hoover-fong, MD Po Box 64316, Baltimore, MD 21264-4316 Ph: () - | Julie Hoover-fong, MD 600 N Wolfe St, Baltimore, MD 21287-0005 Ph: (410) 955-3071 |
News Archive
As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.
The Canadian Diabetes Association applauds the Government of Saskatchewan for increasing access to insulin detemir for residents of Saskatchewan living with diabetes. Insulin detemir, also known as Levemir, has been added to the Saskatchewan Drug Formulary, under Exception Drug Status (EDS) effective July 1, 2009. As well, the updated formulary now includes NovoRapid-NOO, Apidra-AVT and Humalog-LIL within its Revised Exception Drug Status Criteria.
Unfortunately, there are too many examples that show how our system can fail to meet patients' needs. These problems are not a reflection on the many doctors, nurses and other professionals who work tirelessly to deliver the highest quality care they can.
Compugen Ltd., a leading predictive drug discovery company, today presented new data for its preclinical CGEN-15029 program demonstrating the potential for the development of new cancer immunotherapy treatments for solid tumors, including the potential for drug combination with current immune checkpoint blockers.
› Verified 4 days ago